Ata uhi

Lipoprotein Lipase and PPAR Alpha Gene Polymorphisms, Increased Very-Low-Density Lipoprotein Levels, and Decreased High-Density Lipoprotein Levels as Risk Markers for the Development of Visceral Leishmaniasis by Leishmania infantum

In visceral leishmaniasis (VL) endemic areas, a minority of infected individuals progress to disease since most of them develop protective immunity. Therefore, we investigated the risk markers of VL within nonimmune sector. Analyzing infected symptomatic and, asymptomatic, and noninfected individual...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Márcia Dias Teixeira Carvalho (Author), Diego Peres Alonso (Author), Célia Maria Vieira Vendrame (Author), Dorcas Lamounier Costa (Author), Carlos Henrique Nery Costa (Author), Guilherme Loureiro Werneck (Author), Paulo Eduardo Martins Ribolla (Author), Hiro Goto (Author)
Hōputu:	Pukapuka
I whakaputaina:	Hindawi Limited, 2014-01-01T00:00:00Z.
Ngā marau:	article
Urunga tuihono:	Connect to this object online.
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
mā: Niki Katsiki, me ētahi atu.
I whakaputaina: (2023)

Monocyte/high-density lipoprotein cholesterol, neutrophil/high-density lipoprotein cholesterol, and lymphocyte/high-density lipoprotein cholesterol ratios as new inflammatory markers in rosacea
mā: Bülent Nuri Kalaycı
I whakaputaina: (2023)

Serum lipid, lipoprotein and oxidatively modified low density lipoprotein levels in active or inactive patients with behçet's disease
mā: Fuat Cimen, me ētahi atu.
I whakaputaina: (2012)

High Density Lipoproteins From Biological Understanding to Clinical Exploitation
I whakaputaina: (2015)

High Density Lipoproteins From Biological Understanding to Clinical Exploitation /
I whakaputaina: (2015)

High Density Lipoproteins From Biological Understanding to Clinical Exploitation
I whakaputaina: (2015)

Low-Density Lipoproteins Oxidation and Endometriosis
mā: Grzegorz Polak, me ētahi atu.
I whakaputaina: (2013)

Do high-density lipoprotein cholesterol levels really reflect cardioprotection?
mā: Vaishali Venkatesh Dhat, me ētahi atu.
I whakaputaina: (2023)

The Role of High-Density Lipoprotein in COVID-19
mā: Guyi Wang, me ētahi atu.
I whakaputaina: (2021)

Triglyceride to high-density lipoprotein cholesterol and low-density lipoprotein cholestrol to high-density lipoprotein cholesterol ratios are predictors of cardiovascular risk in Iranian adults: Evidence from a population-based cross-sectional study
mā: Karimollah Hajian-Tilaki, me ētahi atu.
I whakaputaina: (2020)

Lower Low-Density Lipoprotein Cholesterol Levels Are Associated with Severe Dengue Outcome.
mā: Hope H Biswas, me ētahi atu.
I whakaputaina: (2015)

Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b for cardiovascular risk assessment - What is the right choice?
mā: Shrikanth N Hegde
I whakaputaina: (2020)

Protective Role of High-Density Lipoprotein in Multiple Sclerosis
mā: Agnieszka Damiza-Detmer, me ētahi atu.
I whakaputaina: (2024)

GENETICALLY PREDICTED LIPOPROTEIN(A) IS ASSOCIATED WITH CORONARY ARTERY PLAQUE SEVERITY INDEPENDENT OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL
mā: Shoa L. Clarke, MD, PhD
I whakaputaina: (2024)

Does Pentraxin-3 contribute to the reduction of low-density lipoprotein levels by statin therapy?
mā: Vuković-Dejanović Vesna, me ētahi atu.
I whakaputaina: (2022)

Significance of Decreased Serum High-density Lipoprotein Cholesterol Levels in Patients with Gastric Cancer
mā: Tae Ho Kim
I whakaputaina: (2022)

Risk assessment of metabolic syndrome in adolescents using the triglyceride/high-density lipoprotein cholesterol ratio and the total cholesterol/high-density lipoprotein cholesterol ratio
mā: Shou-Yu Chu, me ētahi atu.
I whakaputaina: (2019)

SUBFRACTION DISTRIBUTION OF APO B-CONTAINING LIPOPROTEINS DEPENDING ON THE ACHIEVEMENT OF THE TARGET LEVEL OF LOW DENSITY LIPOPROTEINS UNDER STATINS THERAPY IN PATIENTS WITH CORONARY ATHEROSCLEROSIS
mā: I. N. Ozerova, me ētahi atu.
I whakaputaina: (2017)

High-Density Lipoprotein (HDL) Triglyceride and Oxidized HDL: New Lipid Biomarkers of Lipoprotein-Related Atherosclerotic Cardiovascular Disease
mā: Fumiaki Ito, me ētahi atu.
I whakaputaina: (2020)

Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and kidney stone: evidence from NHANES 2007-2018
mā: Tao Chen, me ētahi atu.
I whakaputaina: (2024)

Radical Oxygen Species, Oxidized Low-Density Lipoproteins, and Lectin-like Oxidized Low-Density Lipoprotein Receptor 1: A Vicious Circle in Atherosclerotic Process
mā: Marco Munno, me ētahi atu.
I whakaputaina: (2024)

Triglycerides and high-density lipoprotein cholesterol are associated with insulinemia in adolescents
mā: Ramírez-López Guadalupe, me ētahi atu.
I whakaputaina: (2006)

Primary genetic disorders affecting high density lipoprotein (HDL)
mā: Constantine E Kosmas, me ētahi atu.
I whakaputaina: (2018)

Development of activated endothelial targeted high-density lipoprotein nanoparticles
mā: Minzhi Yu, me ētahi atu.
I whakaputaina: (2022)

High -density lipoprotein cholesterol as a predictor for diabetes mellitus
mā: Hong Wu, me ētahi atu.
I whakaputaina: (2018)

The Role of Oxidized Low-Density Lipoproteins in Atherosclerosis: The Myths and the Facts
mā: Giuseppe Maiolino, me ētahi atu.
I whakaputaina: (2013)

Altered composition and functional profile of high-density lipoprotein in leprosy patients.
mā: Robertha Mariana R Lemes, me ētahi atu.
I whakaputaina: (2020)

Increased serum oxidized low-density lipoprotein levels in pregnancies complicated by gestational diabetes mellitus
mā: Azam Ghaneei, me ētahi atu.
I whakaputaina: (2015)

Possibilities of using rosuvastatin to achieve target level of low-density lipoprotein cholesterol in clinical practice
mā: Yuliia A. Prus, me ētahi atu.
I whakaputaina: (2020)

Serum Low-Density Lipoprotein Cholesterol Levels are Associated with Relapse in Neuromyelitis Optica Spectrum Disorder
mā: Ding J, me ētahi atu.
I whakaputaina: (2024)

Jogging and weight training associated with increased high-density lipoprotein cholesterol levels in Taiwanese adults
mā: Chien-Chang Ho, me ētahi atu.
I whakaputaina: (2022)

Trypanosoma cruzi utilizes the host low density lipoprotein receptor in invasion.
mā: Fnu Nagajyothi, me ētahi atu.
I whakaputaina: (2011)

High-Density Lipoprotein Cholosterol May Discriminate Mild and Severe Preeclampsia
mā: Esra Can, me ētahi atu.
I whakaputaina: (2011)

Low-density lipoprotein nanomedicines: mechanisms of targeting, biology, and theranostic potential
mā: Lin Di, me ētahi atu.
I whakaputaina: (2021)

Structural insights into high density lipoprotein: Old models and new facts
mā: Valentin eGogonea
I whakaputaina: (2016)

Reconstituted high-density lipoproteins: novel biomimetic nanocarriers for drug delivery
mā: Xinyi Ma, me ētahi atu.
I whakaputaina: (2018)

Hypertriglyceridemia promotes dysfunctions in high-density lipoprotein increasing the cardiovascular risk
mā: Richard Rarison Cavalcante Meneses, me ētahi atu.
I whakaputaina: (2023)

Protective Effect of Lusianthridin on Hemin-Induced Low-Density Lipoprotein Oxidation
mā: Su Wutyi Thant, me ētahi atu.
I whakaputaina: (2021)

Low-Density Lipoprotein Modified by Myeloperoxidase in Inflammatory Pathways and Clinical Studies
mā: Cédric Delporte, me ētahi atu.
I whakaputaina: (2013)

Electrochemical immunosensing of low-density lipoprotein based on sol-gel encapsulation
mā: Elton Max Nascimento do Egito, me ētahi atu.
I whakaputaina: (2023)